Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPRI-CF113 contraceptive efficacy trial over 13 cycles
2026-525727-24-00Phase 3Authorised
- Sponsor
- Chemo
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of LPRI-CF113 and drospirenone, sponsored by Chemo. Primary endpoint: Pearl Index in non-breastfeeding women aged 35 years or younger. Planned start Sep 2026; status: authorised.
02
Drugs
LPRI-CF113drospirenone
Beyond the preview
Go deeper on 2026-525727-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525727-24-00.